Toleranzia AB Logo

Toleranzia AB

TOL.ST

(1.2)
Stock Price

0,54 SEK

-153.49% ROA

-3.53% ROE

-17.04x PER

Market Cap.

99.251.286,00 SEK

0% DER

0% Yield

-20.54% NPM

Toleranzia AB Stock Analysis

Toleranzia AB Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Toleranzia AB Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.34x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-6.42%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-8.12%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Toleranzia AB Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Toleranzia AB Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Toleranzia AB Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Toleranzia AB Revenue
Year Revenue Growth
2012 6.227.658
2013 3.164.972 -96.77%
2014 309.004 -924.25%
2015 66.010 -368.12%
2016 3.631.026 98.18%
2017 2.532.330 -43.39%
2018 4.277.883 40.8%
2019 6.949.437 38.44%
2020 12.881.500 46.05%
2021 27.589.000 53.31%
2022 0 0%
2022 35.367.000 100%
2023 0 0%
2023 50.920.000 100%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Toleranzia AB Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Toleranzia AB General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 0
2013 0 0%
2014 937.262 100%
2015 4.690.121 80.02%
2016 6.126.392 23.44%
2017 5.327.218 -15%
2018 6.504.507 18.1%
2019 8.640.342 24.72%
2020 14.560.977 40.66%
2021 29.810.635 51.16%
2022 36.526.216 18.39%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Toleranzia AB EBITDA
Year EBITDA Growth
2012 79.212
2013 74.767 -5.95%
2014 -755.494 109.9%
2015 -4.071.172 81.44%
2016 -4.992.851 18.46%
2017 -5.337.389 6.46%
2018 -5.610.373 4.87%
2019 -5.173.278 -8.45%
2020 -4.874.513 -6.13%
2021 -6.198.161 21.36%
2022 -8.271.704 25.07%
2022 -8.420.000 1.76%
2023 -4.112.000 -104.77%
2023 -7.398.000 44.42%
2024 -8.167.996 9.43%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Toleranzia AB Gross Profit
Year Gross Profit Growth
2012 1.138.567
2013 1.508.713 24.53%
2014 1.374.606 -9.76%
2015 1.288.817 -6.66%
2016 6.346.179 79.69%
2017 5.064.660 -25.3%
2018 8.555.766 40.8%
2019 12.939.239 33.88%
2020 25.023.407 48.29%
2021 54.705.062 54.26%
2022 32.315.496 -69.28%
2022 70.624.000 54.24%
2023 39.168.000 -80.31%
2023 -919.000 4362.02%
2024 -68.000 -1251.47%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Toleranzia AB Net Profit
Year Net Profit Growth
2012 40.196
2013 38.959 -3.18%
2014 -737.223 105.28%
2015 -4.109.695 82.06%
2016 -5.055.571 18.71%
2017 -5.391.991 6.24%
2018 -5.657.963 4.7%
2019 -9.929.020 43.02%
2020 -4.894.585 -102.86%
2021 -6.283.865 22.11%
2022 -8.287.688 24.18%
2022 -8.456.000 1.99%
2023 -4.396.000 -92.36%
2023 -7.459.000 41.06%
2024 -6.472.000 -15.25%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Toleranzia AB Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 -1 0%
2018 0 0%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Toleranzia AB Free Cashflow
Year Free Cashflow Growth
2012 0
2013 0 0%
2014 -2.209.025 100%
2015 -4.585.641 51.83%
2016 -8.147.376 43.72%
2017 -5.863.774 -38.94%
2018 -9.116.370 35.68%
2019 -10.358.673 11.99%
2020 -15.532.250 33.31%
2021 -33.163.421 53.16%
2022 -42.341.000 21.68%
2023 -9.658.000 -338.4%
2023 -57.101.000 83.09%
2024 -7.454.000 -666.05%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Toleranzia AB Operating Cashflow
Year Operating Cashflow Growth
2012 0
2013 0 0%
2014 -935.224 100%
2015 -3.361.268 72.18%
2016 -5.251.146 35.99%
2017 -5.605.743 6.33%
2018 -4.822.947 -16.23%
2019 -4.432.966 -8.8%
2020 -3.991.297 -11.07%
2021 -6.849.365 41.73%
2022 -7.200.000 4.87%
2023 134.000 5473.13%
2023 -6.323.000 102.12%
2024 -40.000 -15707.5%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Toleranzia AB Capital Expenditure
Year Capital Expenditure Growth
2012 0
2013 0 0%
2014 1.273.801 100%
2015 1.224.373 -4.04%
2016 2.896.230 57.73%
2017 258.031 -1022.43%
2018 4.293.423 93.99%
2019 5.925.707 27.55%
2020 11.540.953 48.65%
2021 26.314.056 56.14%
2022 35.141.000 25.12%
2023 9.792.000 -258.87%
2023 50.778.000 80.72%
2024 7.414.000 -584.89%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Toleranzia AB Equity
Year Equity Growth
2012 90.196
2013 852.155 89.42%
2014 1.717.932 50.4%
2015 24.451.237 92.97%
2016 20.058.608 -21.9%
2017 14.666.617 -36.76%
2018 27.585.049 46.83%
2019 34.987.269 21.16%
2020 67.923.487 48.49%
2021 127.965.221 46.92%
2022 125.893.299 -1.65%
2022 119.509.000 -5.34%
2023 155.544.000 23.17%
2023 153.518.000 -1.32%
2024 151.114.000 -1.59%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Toleranzia AB Assets
Year Assets Growth
2012 1.898.240
2013 1.804.404 -5.2%
2014 3.135.706 42.46%
2015 27.257.005 88.5%
2016 22.284.293 -22.31%
2017 16.772.308 -32.86%
2018 30.387.550 44.81%
2019 38.651.920 21.38%
2020 72.575.582 46.74%
2021 132.229.590 45.11%
2022 131.536.527 -0.53%
2022 125.632.000 -4.7%
2023 163.996.000 23.39%
2023 160.427.000 -2.22%
2024 156.340.000 -2.61%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Toleranzia AB Liabilities
Year Liabilities Growth
2012 1.808.044
2013 952.249 -89.87%
2014 1.417.774 32.83%
2015 2.805.768 49.47%
2016 2.225.685 -26.06%
2017 2.105.691 -5.7%
2018 2.802.501 24.86%
2019 3.664.651 23.53%
2020 4.652.095 21.23%
2021 4.264.369 -9.09%
2022 5.643.228 24.43%
2022 6.123.000 7.84%
2023 8.452.000 27.56%
2023 6.909.000 -22.33%
2024 5.226.000 -32.2%

Toleranzia AB Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.13
Net Income per Share
-0.03
Price to Earning Ratio
-17.04x
Price To Sales Ratio
3.77x
POCF Ratio
-14.02
PFCF Ratio
-2.49
Price to Book Ratio
0.61
EV to Sales
3.68
EV Over EBITDA
-13.85
EV to Operating CashFlow
-14.74
EV to FreeCashFlow
-2.43
Earnings Yield
-0.06
FreeCashFlow Yield
-0.4
Market Cap
0,10 Bil.
Enterprise Value
0,10 Bil.
Graham Number
0.69
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.03
Income Quality
1.22
ROE
-0.04
Return On Assets
-0.03
Return On Capital Employed
-0.05
Net Income per EBT
1
EBT Per Ebit
0.74
Ebit per Revenue
-0.28
Effective Tax Rate
-0.03

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
1.37
Operating Profit Margin
-0.28
Pretax Profit Margin
-0.21
Net Profit Margin
-0.21

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.03
Free CashFlow per Share
-0.2
Capex to Operating CashFlow
-5.06
Capex to Revenue
1.26
Capex to Depreciation
853.82
Return on Invested Capital
-0.05
Return on Tangible Assets
-1.53
Days Sales Outstanding
13.63
Days Payables Outstanding
-106.37
Days of Inventory on Hand
0
Receivables Turnover
26.77
Payables Turnover
-3.43
Inventory Turnover
0
Capex per Share
0.17

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,77
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
0.77
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.33
Current Ratio
0.63
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
151115000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.98
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-593499.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Toleranzia AB Dividends
Year Dividends Growth

Toleranzia AB Profile

About Toleranzia AB

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. In addition, the company develops tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating various autoimmune diseases. The company was founded in 2011 and is headquartered in Gothenburg, Sweden.

CEO
Ms. Charlotte Fribert
Employee
10
Address
Erik Dahlbergsgatan 11A
Gothenburg, 411 26

Toleranzia AB Executives & BODs

Toleranzia AB Executives & BODs
# Name Age
1 Mr. Thomas Palsson M.Sc.
Chief Financial Officer (Leave of Absence)
70
2 Ms. Charlotte Fribert
Chief Executive Officer & Executive Director
70
3 Ms. Ann-Sofie Taube
Interim Chief Financial Officer
70
4 Dr. Vidar Wendel-Hansen M.D., Ph.D.
Chief Medical Officer
70
5 Dr. Björn Löwenadler Ph.D.
Chief Business Officer
70

Toleranzia AB Competitors

Gabather AB (publ) Logo
Gabather AB (publ)

GABA.ST

(1.0)
CombiGene AB (publ) Logo
CombiGene AB (publ)

COMBI.ST

(1.2)
Nanexa AB (publ) Logo
Nanexa AB (publ)

NANEXA.ST

(1.8)
Sprint Bioscience AB (publ) Logo
Sprint Bioscience AB (publ)

SPRINT.ST

(1.0)